- Home
- »
- Medical Devices
- »
-
Botulinum Toxin In Urology Market Size Report, 2026-2033GVR Report cover
Botulinum Toxin In Urology Market (2026 - 2033)
Size, Share & Trends Analysis Report By Application (Overactive Bladder, Neurogenic Detrusor Overactivity), By End Use (Hospitals, Urology Clinics), By Region, And Segment Forecasts
Market Size, 2025
$1.1BMarket Estimate, 2026
$1.2BMarket Forecast, 2033
$1.7BCAGR, 2026–2033
5.6%Botulinum Toxin In Urology Market Summary
The global botulinum toxin in urology market size was valued at USD 1.1 billion in 2025 and is projected to grow from USD 1.2 billion in 2026 to USD 1.7 billion by 2033, at a CAGR of 5.6% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 40.7% in 2025. Botulinum toxin is produced by the bacterium Clostridium botulinum.
Source: Grand View Research, IR Documents, Primary Interviews, Paid DatabasesTo learn more about this report,
Download Free Sample Report Key Market Trends & Insights
- By end use: Hospitals segment held the largest market share of 74.0% in 2025.
- By application: Overactive bladder segment held the largest market share of 67.5% in 2025.
Regional Highlights
- Largest regional market: North America (40.7% revenue share, 2025)
- Fastest-growing regional market: Asia Pacific (highest CAGR, 2026-2033)
- By country: The U.S. held the largest market share in 2025.
Market Size & Forecast
- Market size in 2025: USD 1.1 Billion
- Estimated market size in 2026: USD 1.2 Billion
- Projected market size by 2033: USD 1.7 Billion
- CAGR (2026-2033): 5.6%
Prism AI by Grand View Research Free to tryAsk a question about the botulinum toxin in urology marketTry asking✓Every figure cited from GVR research Prefer the report? Download free sample →
When injected into muscle, it acts as a specific blocker of acetylcholine produced from nerves, which prevents neural transmission from the nerves. Due to factors such as the increasing geriatric population, increase in the number of botulinum toxin procedures, and growing prevalence of neurogenic urologic disorders such as refractory urinary incontinence, urgency, and frequency, the demand for botulinum toxin is growing.
To learn more about this report, Download Free Sample Report The rise in the use of botulinum toxin injection in several lower urinary tract conditions, including the treatment of overactive bladders, bladder pain syndrome, pediatric urinary incontinence, and others, is projected to boost the market growth during the forecast period. The availability of various botulinum toxin products such as disport, botox, and others is expected to accelerate the market growth. For instance, in June 2022, according to MDPI, the product botulinum toxin type A (BoNT-A) in various preparations was used to treat urinary tract conditions.
Globally, the increasing geriatric population associated with urinary tract conditions, especially urinary incontinence, is projected to impact the market's growth. The senior population, particularly those aged 65 and above, is more prone to urinary incontinence problems, requiring botulinum toxin injections to treat these conditions. For instance, in November 2022, the article" Senior Population Statistics: A Portrait of Aging Americans," reported that around 54.1 million (16.3%) individuals in the U.S. are aged 65 or above. Thus, the growing geriatric population is attributed to the increasing demand for botulinum toxin injections. In addition, rising investment in the R&D program by key market players to explore the therapeutic use of botulinum toxin in urinary tract conditions is building opportunities for expanding its market over the forecast period.
The COVID-19 pandemic has had a major impact on healthcare systems, including the market for botulinum toxin. Market players have experienced huge losses due to the cancellation or postponement of urinary treatments. For instance, in July 2022, according to NCBI, it is reported that the Italian Society of Urodynamics found that approximately 78.4% of treatments regarding urology investigations, procedures, and consultations were canceled during a pandemic. After the pandemic, the growing number of individuals receiving treatment for urinary tract conditions increased the demand for botulinum toxin injection.
Market Dynamics
The botulinum toxin in urology market is experiencing significant growth driven by the increasing prevalence of overactive bladder (OAB), neurogenic detrusor overactivity (NDO), urinary incontinence, and other lower urinary tract disorders, coupled with the growing preference for minimally invasive treatment options. The market is further supported by an aging global population, rising incidence of neurological conditions affecting bladder function, increasing awareness regarding advanced urological therapies, and continuous expansion of evidence-based clinical applications for botulinum toxin products. Botulinum toxin therapies enable urologists, hospitals, specialty clinics, ambulatory surgical centers, and integrated healthcare systems to effectively manage complex bladder dysfunctions through targeted neuromuscular intervention. These therapies are widely utilized for the treatment of overactive bladder, neurogenic bladder disorders associated with spinal cord injury and multiple sclerosis, refractory urge urinary incontinence, detrusor overactivity, and other conditions where conventional pharmacological therapies provide inadequate symptom control, offering a clinically proven alternative to more invasive surgical interventions.
The rising prevalence of overactive bladder (OAB) and urinary incontinence is a major factor driving growth in the global botulinum toxin in urology market. OAB affects millions of individuals worldwide and is characterized by symptoms such as urinary urgency, increased urinary frequency, nocturia, and urge urinary incontinence, which can significantly impair quality of life and daily functioning. The burden of these conditions is increasing due to population aging, growing incidence of obesity, diabetes, neurological disorders, and other chronic diseases that contribute to bladder dysfunction. While first-line treatments such as behavioral therapy and oral medications remain widely used, many patients experience inadequate symptom control or discontinue treatment due to limited efficacy and adverse effects. Consequently, botulinum toxin injections have emerged as an effective and minimally invasive treatment option for patients with refractory OAB and urinary incontinence. Clinical studies have consistently demonstrated that botulinum toxin therapy can reduce incontinence episodes, improve bladder capacity, decrease urgency symptoms, and enhance patient quality of life. As awareness, diagnosis rates, and treatment-seeking behavior continue to increase globally, the growing patient pool suffering from OAB and urinary incontinence is expected to drive sustained demand for botulinum toxin therapies across hospitals, specialty urology clinics, and ambulatory care settings.
One of the primary restraints limiting the growth of the botulinum toxin in urology market is the relatively high cost of treatment, particularly for patients requiring long-term management of chronic bladder disorders such as overactive bladder (OAB) and neurogenic detrusor overactivity (NDO). Although botulinum toxin therapy provides significant symptom relief, its therapeutic effects are temporary, typically requiring repeat injections every 6-12 months to maintain clinical benefits. The cumulative cost associated with repeated procedures, physician visits, and follow-up care can create a substantial financial burden for patients and healthcare systems. In addition, reimbursement coverage remains inconsistent across several developing and emerging markets, limiting treatment accessibility and adoption. These economic challenges, combined with the availability of less expensive pharmacological alternatives, continue to restrain broader market penetration, particularly in cost-sensitive healthcare environments.
Analyst Perspective
The global botulinum toxin in urology market is driven by the rising prevalence of overactive bladder (OAB), neurogenic detrusor overactivity (NDO), urinary incontinence, and other lower urinary tract disorders, along with growing demand for effective non-surgical treatments. Increasing bladder health awareness, diagnosis rates, and advances in urological care are creating opportunities for pharmaceutical manufacturers, healthcare providers, and specialty clinics. Market growth is further supported by age-related bladder dysfunction, neurological disorders, obesity, diabetes, and other chronic conditions. Botulinum toxin therapies offer targeted bladder muscle modulation, reducing involuntary contractions, urinary urgency, and frequency while improving quality of life. Growing preference for minimally invasive outpatient procedures, along with clinical guideline inclusion and broader reimbursement support, is further accelerating adoption.
Application Insights
Based on application, the market is bifurcated intooveractive bladder and neurogenic detrusor overactivity segments. In 2025, the overactive bladder segment held the largest revenue share at 67.5%. Factors such as incomplete bladder emptying, overweight, obesity, and urinary tract infections, contribute to overactive bladder. For instance, according to the Cleveland Clinic, in the U.S., about 33 million adults are affected by overactive bladder, including 40% of women and 30% of men. Thus, the growing incidence of overactive bladder boosts the market growth.
Individuals with Parkinson's disease, multiple sclerosis, and Spina bifida are more vulnerable to neurogenic detrusor overactivity. For instance, according to the Cleveland Clinic, neurogenic detrusor overactivity affects more than 90% of people and is common with spinal cord injuries. Approximately 50% to 80% of people with multiple sclerosis and 95% with spina bifida have neurogenic detrusor overactivity. Thus, the increasing prevalence of chronic diseases has led to a rise in neurogenic detrusor overactivity problems, further resulting in market growth over the forecast period.
End-use Insights
Based on end-use, the market is bifurcated into Hospitals and urology clinics segments. The Hospitals segment held the largest revenue share of 74.0% in 2025 and is projected to grow at the fastest CAGR over the forecast period. Increasing awareness for applications of botulinum toxin in urinary conditions, rising elderly population, and a growing number of Hospitals in developed and emerging nations are attributed to the segment growth. For instance, in August 2023, according to NVBI, it is stated that 11% of Hospitalized elderly patients have urinary incontinence at admission and 23% at discharge. Hospitals play a vital role in specialized medical care for diagnosing and treating urinary tract conditions, thus fueling market growth.
To learn more about this report, Download Free Sample Report The urology clinics offer diagnostic testing and therapies for conditions affecting the genitourinary system and urinary bladder. Patients preferring more specialized Hospitals to gain more precise and accurate treatment boost the market growth.
Regional Insights
North America dominated the botulinum toxin in urology market with the largest revenue share of 40.7% in 2025 due to several factors, including a growing elderly population, increasing prevalence of urinary incontinence, strong presence of industry players in the region, well-developed healthcare infrastructure, and rising awareness among the public. For instance, in August 2023, according to an article titled “Urinary Incontinence,” it was reported that around 13 million Americans suffer from urinary incontinence, and the prevalence is 50% or above among residents of nursing facilities. Thus, the rising prevalence of urinary incontinence is driving the market growth in the region.
To learn more about this report, Download Free Sample Report The Asia Pacific region is anticipated to register the fastest CAGR of 6.6% over the forecast period due to several contributing factors. An aging population, high consumption of beverages such as tea and coffee, and diabetes are leading to increased urinary incontinence. For instance, in November 2022, according to the World Health Organization (WHO), in the Southeast Asia region, more than 96 million individuals are predicted to have diabetes, with another 96 million pre-diabetic individuals causing at least 600,000 casualties annually. These factors create a higher demand for effective treatment options such as botulinum toxin type A (BoNT-A) in the Asia Pacific region.
Key Companies & Market Share Insights
The global botulinum toxin in the urology industry is competitive and highly regulated. The major key players in the market are implementing strategic initiatives, such as acquisitions, mergers, product approval, new product launches, partnerships, and collaborations, to maximize their market dominance. For instance, in February 2021, AbbVie Inc. received approval from the U.S. Food and Drug Administration (FDA) for its BOTOX (Onabotulinumtoxin A) to treat neurogenic detrusor overactivity in pediatric patients.
Key Botulinum Toxin In Urology Companies
The following key companies have been profiled for this study on the botulinum toxin in urology market:
-
AbbVie Inc.
-
Merz Pharma
-
Ipsen Pharma
-
GALDERMA
-
Allergan PLC
-
Sun Pharmaceutical Industries Ltd.
-
Biovencer Healthcare Pvt Ltd
Competitive Benchmarking
Category
Operating Strategies
Competitive Edge
Weakness
Established Players (AbbVie Inc., Merz Pharma, Ipsen Pharma)
- They focus on expanding therapeutic indications, generating long-term clinical data, strengthening physician education programs, and investing in lifecycle management strategies to maintain leadership in neurotoxin-based urological treatments. These companies also emphasize geographic expansion and reimbursement support to increase adoption across hospitals and specialty urology centers.Strong distribution networks and established customer relationships enable sustained revenue growth and market leadership.
- Mature companies benefit from strong brand recognition, proven safety and efficacy profiles, large-scale production capacity, and extensive regulatory approvals.
- Their broad physician relationships, comprehensive training programs, and established distribution infrastructure enable widespread adoption of botulinum toxin therapies for overactive bladder (OAB), neurogenic detrusor overactivity (NDO), and other urinary dysfunction indications.
- Large organizations may face slower innovation cycles due to complex corporate structures and extensive regulatory requirements.
- Dependence on a limited number of flagship neurotoxin products can expose them to competitive pressures from biosimilars, emerging toxin formulations, and pricing challenges.
Emerging Players (Sun Pharmaceutical Industries Ltd., Biovencer Healthcare Pvt Ltd)
- Emerging players prioritize next-generation botulinum toxin development, formulation innovation, and strategic partnerships with healthcare providers and research institutions.
- They focus on improving duration of action, reducing immunogenicity, optimizing dosing protocols, and developing differentiated products targeting unmet needs in urological disorders.
- Emerging companies gain traction through technological innovation, development of novel toxin serotypes or extended-duration formulations, and flexible commercialization strategies.
- Their streamlined operations enable faster product development and adaptation to evolving clinical requirements.
- Regulatory approval pathways can be lengthy and resource-intensive, while restricted financial resources may limit large-scale clinical trials and global market expansion.
- They also face significant competition from well-established toxin manufacturers with entrenched physician loyalty and reimbursement support.
Botulinum Toxin In Urology Market Report Scope
Report Attribute
Details
Market size in 2025
USD 1.1 billion
Estimated market size in 2026
USD 1.2 billion
Projected market size by 2033
USD 1.7 billion
Growth rate
CAGR of 5.6% from 2026 to 2033
Historical data
2021 - 2024
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million/billion and CAGR from 2026 to 2033
Report coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered
Application, end use, region
Regional scope
North America; Europe; Asia Pacific; Latin America; MEA
Country scope
U.S.; Canada; Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Australia; Thailand; Brazil; Mexico, Argentina; South Africa; Saudi Arabia, UAE; Kuwait
Key companies profiled
AbbVie Inc.; Merz Pharma; Ipsen Pharma; GALDERMA; Allergan PLC; Sun Pharmaceutical Industries Ltd.; Biovencer Healthcare Pvt Ltd
Customization scope
Free report customization (equivalent up to 8 analysts' working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
Global Botulinum Toxin In Urology Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global botulinum toxin in urology market report based on application, end-use, and region:
To learn more about this report, Download Free Sample Report -
Application Outlook (Revenue, USD Million, 2021 - 2033)
-
Overactive Bladder
-
Neurogenic Detrusor Overactivity
-
-
End-use Outlook (Revenue, USD Million, 2021 - 2033)
-
Hospitals
-
Urology Clinics
-
-
Regional Outlook (Revenue, USD Million, 2021 - 2033)
-
North America
-
U.S.
-
Canada
-
-
Europe
-
UK
-
Germany
-
France
-
Italy
-
Spain
-
Denmark
-
Sweden
-
Norway
-
-
Asia Pacific
-
Japan
-
China
-
India
-
South Korea
-
Australia
-
Thailand
-
-
Latin America
-
Brazil
-
Mexico
-
Argentina
-
-
Middle East & Africa
-
South Africa
-
Saudi Arabia
-
UAE
-
Kuwait
-
-
Research Methodology
The botulinum toxin in urology market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each botulinum toxin in urology segment quantified using the revenue-capture definitions in the table below.
Segment Definition
Segment - Application
Revenue capture definition
Overactive Bladder
Revenue is generated through the commercialization and clinical utilization of botulinum toxin type A vials specifically indicated for patients with refractory idiopathic overactive bladder who cannot tolerate or fail anticholinergic systemic therapies. Pharmaceutical manufacturers capture upfront product revenue through the sale of standardized 100-unit or 200-unit lyophilized vials to medical facilities. Because the neurotoxic blockade of acetylcholine release in the detrusor muscle is transient, companies capture highly stable, predictable, and recurring revenue streams stemming from patient re-injection cycles occurring every 6 to 9 months.
Neurogenic Detrusor Overactivity
Revenue flows from the procurement of high-potency botulinum toxin formulations indicated for the management of bladder hyperactivity secondary to underlying neurological conditions, such as spinal cord injuries, transverse myelitis, or multiple sclerosis. Revenue is captured through the institutional sales of higher dosage tiers. Device and pharmaceutical developers maximize financial pull-through by cross-selling or bundling the biological agent with mandatory specialized cystoscopic delivery needles and intravesical instillation accessories required to map and execute multiple precise injections directly into the detrusor wall.
Segment - End-use
Revenue capture definition
Hospitals
Revenue is generated through high-volume institutional procurement cycles, public or private healthcare system tenders, and restrictive hospital formulary contract listings. Revenue capture in this ecosystem is characterized by centralized purchasing models and bulk multi-departmental supply contracts, serving complex neurogenic (NDO) patient bases who require specialized inpatient or outpatient operative surgical suites equipped with rigid or flexible video-cystoscopy towers, specialized anesthesia workflows, and intensive post-procedural urinary retention monitoring frameworks.
Urology Clinics
Revenue is captured through direct-to-clinic medical sales pipelines, private urological physician buying alliances (GPOs), and specialized urology franchise accounts. Manufacturers secure highly lucrative, agile commercial revenue in this segment due to the rapid, high-throughput nature of independent practices. These clinics focus heavily on performing idiopathic Overactive Bladder (OAB) injections under local anesthesia directly in routine outpatient exam lanes, driving consistent, monthly repeating product re-orders and higher per-vial commercial profit margins over institutional hospital tenders.
Estimation Model
Stage
Key Question
Process Steps
Data Sources
Scope Definition
What is being sized within the wearable injectors ecosystem?
1. Define wearable injector type categories.
2. Segment the market by technology type.
3. Define therapeutic application areas, including oncology, autoimmune diseases, cardiovascular disorders, infectious diseases, and others.
4. Establish geographic scope and align on base year and forecast horizon (2026-2033).
FDA approvals, EMA databases, PMDA databases, company annual reports, scientific publications
Build the Product Base
How large is the eligible patient population and therapy volume suitable for injectors?
1. Analyze prevalence and incidence of chronic diseases requiring high-volume subcutaneous drug administration.
2. Quantify patients receiving biologics, biosimilars, long-acting injectables, and peptide therapeutics.
3. Assess transition potential from hospital-based intravenous infusions to at-home subcutaneous delivery.
4. Forecast growth in biologic drug pipelines and self-administration trends.
Disease epidemiology databases, pharmaceutical sales datasets, biologics market reports, healthcare utilization datasets
Estimate Penetration
What proportion of eligible therapies and patients utilize wearable injector technologies?
1. Assess adoption rates of wearable injectors across major therapeutic areas.
2. Analyze physician acceptance, patient preference, and adherence benefits associated with wearable injectors.
3. Quantify penetration of connected and smart wearable injector systems with digital monitoring capabilities.
4. Analyze regional reimbursement support and regulatory approvals influencing adoption.
Primary interviews with pharmaceutical companies, healthcare providers, infusion specialists, payers, and distributors
Revenue Conversion
How do device utilization volumes translate into market revenues?
1. Collect average selling prices (ASP) for disposable and reusable wearable injector platforms.
2. Estimate annual device consumption based on treatment frequency and patient utilization.
3. Evaluate recurring revenues from consumables, software integration, connectivity solutions, and maintenance services.
4. Validate market estimates using manufacturer revenues, shipment data, and industry benchmarks.
Company financial reports, SEC filings, manufacturing pricing data, distributor datasets
Delivered Customizations
This report has been delivered with the following In-depth customizations
Client Request
Customization Delivered
Value Adds
Competitive Landscape Analysis
Conducted a comprehensive competitive landscape assessment of the global botulinum toxin in urology market, covering leading manufacturers, specialty pharmaceutical companies, and biotechnology firms involved in the development and commercialization of botulinum toxin therapies for overactive bladder (OAB), neurogenic detrusor overactivity (NDO), urge urinary incontinence, and other lower urinary tract disorders. The study evaluated company market positioning, product portfolios, approved indications, clinical trial pipelines, pricing strategies, distribution networks, physician engagement initiatives, and regional commercialization approaches. The analysis further assessed regulatory approvals, reimbursement coverage, technological advancements in toxin formulation and delivery techniques, strategic collaborations, licensing agreements, mergers and acquisitions, and investments in expanding therapeutic indications. Additionally, the study examined competitive differentiation based on efficacy, duration of action, safety profiles, patient outcomes, and adoption across hospitals, ambulatory surgical centers, and specialty urology clinics.
Enables stakeholders to understand competitive dynamics, innovation trends, and strategic positioning of key participants within the botulinum toxin in urology market. The study supports informed decision-making related to product development, market entry strategies, partnership opportunities, geographic expansion, and investment prioritization. It also assists manufacturers in identifying unmet clinical needs, benchmarking competitor capabilities, evaluating commercialization strategies, and strengthening market penetration across diverse healthcare settings while optimizing portfolio performance and long-term growth initiatives.
Geographic Analysis
Conducted a detailed geographic assessment of the global botulinum toxin in urology market across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The study evaluated regional variations in disease prevalence, healthcare expenditure, reimbursement frameworks, physician awareness, patient access to specialty urology care, and adoption of minimally invasive treatment options. The analysis examined procedure volumes for overactive bladder and neurogenic bladder management, regulatory environments, healthcare infrastructure development, availability of trained urologists, and country-specific treatment guidelines influencing botulinum toxin utilization. Furthermore, the assessment investigated demographic trends, aging populations, prevalence of neurological disorders, healthcare modernization initiatives, and economic conditions impacting market demand. The study also identified high-growth countries, emerging opportunities, market entry barriers, and regional investment priorities shaping future market expansion.
Enables stakeholders to gain a comprehensive understanding of regional demand patterns, growth opportunities, and market maturity levels across major geographies. The study supports strategic planning by identifying priority markets, reimbursement-driven opportunities, healthcare infrastructure gaps, and country-specific adoption trends. It further assists organizations in optimizing regional expansion strategies, resource allocation, pricing models, regulatory planning, and distribution networks while mitigating geographic risks and capitalizing on emerging growth markets within the global urology therapeutics landscape.
Porters Analysis
Conducted a detailed Porter’s Five Forces assessment of the global botulinum toxin in urology market to evaluate the competitive intensity and long-term attractiveness of the industry. The study analyzed the bargaining power of suppliers, including manufacturers of biologic active pharmaceutical ingredients and specialized production technologies; the bargaining power of buyers such as hospitals, healthcare systems, specialty clinics, and reimbursement agencies; the threat of new entrants considering stringent regulatory requirements, clinical evidence generation, manufacturing complexities, and intellectual property barriers; the threat of substitute therapies including oral pharmacotherapies, neuromodulation procedures, behavioral therapies, and surgical interventions; and the degree of competitive rivalry among established pharmaceutical and biotechnology companies. The analysis also examined reimbursement policies, pricing pressures, healthcare procurement practices, and innovation-driven competition influencing market profitability.
Enables stakeholders to evaluate the structural attractiveness of the botulinum toxin in urology market and understand the key forces influencing revenue growth, pricing flexibility, and competitive positioning. The study provides actionable insights for market entry assessment, investment evaluation, risk management, product differentiation, and strategic planning. It further helps organizations identify competitive advantages, anticipate industry shifts, optimize commercialization strategies, strengthen negotiation capabilities, and develop sustainable growth initiatives amid evolving regulatory, reimbursement, and healthcare economic environments.
Frequently Asked Questions About This Report
The global botulinum toxin in urology market size was valued at USD 1.1 billion in 2025 and is estimated at USD 1.2 billion for 2026.
The global botulinum toxin in urology market is expected to grow at a CAGR of 5.6% from 2026 to 2033, reaching USD 1.7 billion by 2033.
Some of the players operating in this market are AbbVie Inc., Merz Pharma, Ipsen Pharma, GALDERMA, Allergan PLC, Sun Pharmaceutical Industries Ltd., and Biovencer Healthcare Pvt Ltd.
Key factors that are driving the botulinum toxin in urology market growth include the increasing geriatric population associated with urinary tract conditions, increase in number of botulinum toxin procedure, and growing prevalence of neurogenic urologic disorders.
North America dominated the botulinum toxin in urology market with a share of 40.7% in 2025. This is attributable to the growing geriatric population, increasing prevalence of urinary incontinence, and the strong presence of industry players in the region.
Asia Pacific is the fastest-growing region over the forecast period.
The overactive bladder segment led with a 67.5% revenue share in 2025 and is the fastest-growing segment.
The hospitals segment led with a 74.0% revenue share in 2025 and is the fastest-growing segment.
About the Author(s)
Medical Devices Research Team
Healthcare · Medical DevicesThis report was authored by the medical devices research team at Grand View Research - comprising two research analysts, one senior research analyst, and one industry expert - with specialized expertise in the medical devices segment of the healthcare industry. All findings are based on proprietary healthcare databases, executive interviews, and regulatory analysis, subject to internal peer review prior to publication.
Last Updated:
Speak to Analyst
Customize this report to your needs - add regions, segments, or data points, with 20% free customization.
Or view our licence options:
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
